



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
PATENT TRANSMITTAL FORM

GP 2857  
#7

RECEIVED  
DEC 18 2002  
TECHNOLOGY CENTER 2800

Applicant(s): John R. Desjarlais

Serial No.: 10/071,859

Filed: February 6, 2002

For: APPARATUS AND METHOD FOR DESIGNING PROTEINS AND PROTEIN  
LIBRARIES

Examiner: Not Yet Assigned

Art Unit: 2857

Attorney Docket: 823.0093USQ

COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

Dear Sir:

Transmitted herewith is:

1. Supplemental Information Disclosure Statement;
2. PTO Form 1449 with copies of patents;
3. Transmittal letter in duplicate; and
4. Postcard.

Please charge any additional fees or credit any such fees, if necessary to Deposit Account No. 01-0467 in the name of Ohlandt, Greeley, Ruggiero & Perle. A duplicate copy of this sheet is attached.

Respectfully submitted,

Date: December 9, 2002

Paul D. Greeley, Esq.  
Reg. No. 31,019  
Ohlandt, Greeley, Ruggiero & Perle, L.L.P.  
One Landmark Square, 10th Floor  
Stamford, Connecticut 06901-2682  
(203) 327-4500

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE U.S. POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON DECEMBER 9, 2002.

Jeffrey J. Scepanski  
NAME

SIGNATURE

12/09/02  
DATE



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): John R. Desjarlais

Serial No.: 10/071,859

Filed: February 6, 2002

For: APPARATUS AND METHOD FOR DESIGNING PROTEINS AND PROTEIN LIBRARIES

Examiner: Not Yet Assigned

Art Unit: 2857

Attorney Docket: 823.0093USQ

RECEIVED  
DEC 18 2002  
TECHNOLOGY CENTER 2800

**RECEIVED**

DEC 24 2002

TECH CENTER 1600/2900

Commissioner for Patents  
Washington, D.C. 20231

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

In accordance with applicant's duty of disclosure under 37 C.F.R. §1.56, please find attached hereto form PTO-1449 listing information which may be material to the patentability of this application. This Information Disclosure Statement is being filed:

\_\_\_ Within three (3) months of the filing date of the national application;

\_\_\_ Within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application;

**XXX** Before the mailing date of a first Office Action on the merits;

\_\_\_ After the filing date or date of first Office Action, but before the mailing date of a final action under 37 C.F.R. §1.113, provided that this occurs prior to the issuance of a Notice of Allowance and provided that this I.D.S. is accompanied by either a certification as specified in 37 C.F.R. §1.97(e) or the fee set forth in 37 C.F.R. §1.17(p);


— After the filing date or date of first Office Action, but before the mailing date of a Notice of Allowance under 37 C.F.R. §1.311, provided that this occurs prior to the final action and provided that this I.D.S. is accompanied by either a certification as specified in 37 C.F.R. §1.97(e) or the fee set forth in 37 C.F.R. §1.17(p);

— After the mailing date of a final action under 37 C.F.R. §1.113, provided that this occurs prior to the issuance of a Notice of Allowance and provided that this I.D.S. is accompanied by either a certification as specified in 37 C.F.R. §1.97(e), a petition requesting consideration of the I.D.S., and the petition fee set forth in 37 C.F.R. §1.17(i)(1); and

— After the mailing date of a Notice of Allowance under 37 C.F.R. §1.311, provided that this occurs prior to the issuance of a final action and provided that this I.D.S. is accompanied by either a certification as specified in 37 C.F.R. §1.97(e), a petition requesting consideration of the I.D.S., and the petition fee set forth in 37 C.F.R. §1.17(l)(1).

It should be understood that attention has been called to the references that have been deemed to be pertinent to the claimed present invention. In concluding what was pertinent, the criteria employed was considered most appropriate in light of the invention shown in the present application. However, the Examiner or others may deem some other criteria to be just as appropriate or more appropriate. Therefore, the Examiner is respectfully urged to review the listed references and to make the usual careful independent search for other prior art that may be pertinent.

Respectfully submitted,



Date: December 9, 2002

Paul D. Greeley  
Reg. No. 31,019  
Ohlandt, Greeley, Ruggiero & Perle, L.L.P.  
One Landmark Square, 10th Floor  
Stamford, CT 06901-2682  
(203) 327-4500

Sheet 1 of 1.

FORM PTO-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)	Docket Number (Optional)	Application Number
	823.0093USQ	10/071,859
	Applicant	
	John R. Desjarlais	
Filing Date	Group Art Unit	
February 6, 2002	2857	

## U. S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

RECEIVED

DEC 24 2002

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	Kiedrowski et al. "Parabolic growth of a self-replicating Hexadeoxynucleotide bearing a 3'-5'-Phosphoamidate Linkage." Angew. Chem. Int. Ed. Engl. 30 (1991) No. 4, 423-426.
	Meier et al. "Peptide nucleic acids (PNAs)-Unusual properties of nonionic oligonucleotide analogues." Angew. Chem. Int. Ed. Engl. 31 (1992) No. 8, 1008-1010.
	Pauwels et al. "Biological activity of new 2-5 A analogues." Chemica Scripta 1986, 26, 141-145.
	Vasquez. "An evaluation of discrete and continuum search techniques for conformational analysis of side chains in Proteins." Biopolymers. Vol. 36, 53-70 (1995).
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.